Healthcare >> CEO Interviews >> February 7, 2001
FRED D. SANCILIO founded aaiPharma Inc. in 1979 and has served the
company as Director, Chairman of the Board, and Chief Executive Officer
since its inception. He directs the organization in providing full
product development services to the pharmaceutical industry. In addition
to serving on the Board of Directors of several industry-related
organizations, Dr. Sancilio is a member of a Regional Advisory Board for
Bank of America, and of the Board of Visitors for the University of
North Carolina at Wilmington, NC. He is a frequent lecturer for business
and professional groups on subjects ranging from structural activity
relationships of pharmaceutical products to the future direction of the
pharmaceutical industry. Dr. Sancilio started his career as a physical
and analytical chemist in the Research Division of Hoffmann-LaRoche, and
held subsequent positions at Schering-Plough and Burroughs-Wellcome,
prior to the start-up of AAI. He earned his MS and PhD degrees in
Physical and Analytical Chemistry from Rutgers University. Among
professional awards of note, Dr. Sancilio was recently recognized as a
regional 'Entrepreneur of the Year' by Ernst & Young, LLP. He also holds
a distinguished membership in Sigma XI, Scientific Research Society of
North America. Although in recent years Dr. Sancilio has concentrated on
the national and international business aspects of developing chemistry
into medicine, he holds patents in the area of pharmaceutical product
development. Profile
TWST: Could you give us a brief overview and history of the company?Dr. Sancilio: I was the founder of the company in 1979. We grew very
rapidly for the next 10 years, and we went from just